STEPTOE LLP

Lobbying for OREXO US, INC. · Pharmaceuticals / health products

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · New Jersey · House · Senate · $230,000.00 income · posted Apr 19, 2026

Lobbying activity 2

Alcohol and Drug Abuse

Advocacy on xylazine and adultered-opioid overdose solutions and federal funding.

Budget/Appropriations

Advocacy on xylazine and adultered-opioid overdose solutions and federal funding.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.